Patent · US Active

Peptides and related compositions and methods

US11446356B2 · kind B2 · utility

0Cited by
32References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 28, 2020
Grant dateSep 20, 2022
Priority date
Expiry dateFeb 28, 2040

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N33/57492
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α5β1) or vitronectin (αvβ3 and αvβ5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.